Anbio Biotechnology Ltd (NNNN): Rasio kapitalisasi marang pendapatan

Anbio Biotechnology is recognized as a global expert in the development of precision diagnostic systems. This P/S chart illustrates the market valuation of the business, where 17.30 represents the latest level. Market capitalization relies on the sales of portable analyzers and reagents. The company is currently overcoming a decline in demand for COVID tests by redirecting resources toward the production of general clinical laboratory tests.

Anbio Biotechnology generates stable income based on the sale of consumables for installed diagnostic equipment, making revenue a predictable value driver. The ratio of market capitalization to the volume of these sales determines the business's monetization efficiency, allowing the median P/S to assess the degree of overpayment for future operational cash flow growth and avoid capital losses during a trend reversal.